FDA Expands Afrezza to Pediatric Diabetes - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 3 min

Share

Objective:

To inform about the FDA's approval of Afrezza for children and adolescents with diabetes.

Key Findings:
  • Afrezza offers a needle-free mealtime insulin option for pediatric patients.
  • It is recognized in the American Diabetes Association Standards of Care.
  • For type 1 diabetes, Afrezza must be used with basal insulin.
Interpretation:

Afrezza may help clinicians tailor insulin therapy to the daily lives of children and families.

Limitations:
  • Not indicated for treatment of diabetic ketoacidosis.
  • Not for use in patients with chronic lung disease or those who smoke.
  • Safety and efficacy in children younger than 6 years is unknown.
Conclusion:

Afrezza expands treatment options for pediatric diabetes management.

Original Source(s)

FDA Expands Afrezza to Pediatric Diabetes

  • by Kathryn Wighton

  • May 29, 2026

Related Content

American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy

This American Epilepsy Society (AES) practice guideline provides updated, evidence-based recommendations for the management of epilepsy in infants and children aged 1 month to <36 months.

  • by

  • August 14, 2026

  • 2 min
Further Reflections on Metabolically Healthy Obesity in Children

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.